• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

    8.950 +0.040 (+0.45%)
    Streaming Delayed Price Updated: 9:37 AM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Candel Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at Upcoming Investor Conferences
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer ↗
    Via Stocktwits
    News headline image
    Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Pricing of Public Offering
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today ↗
    Candel is pushing ahead with an equity raise and also lined up $100 million in royalty funding from RTW Investments, contingent on FDA approval of CAN-2409. 
    Via Stocktwits
    News headline image
    Candel Therapeutics Announces Proposed $100 Million Public Offering
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗
    Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards ↗
    Trinity Capital Inc. announced a financing agreement with Bobbie, an organic infant nutrition company, to boost production capacity and ensure wider distribution of its products. 
    Via Benzinga
    News headline image
    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at the SITC 2025 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
    From Candel Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.